Eclipse Bioinnovations

What Eclipse Bioinnovations does

Eclipse Bioinnovations (Eclipsebio) is a San Diego-based, privately held RNA genomics company founded in 2017 that provides products and services to academic and industry customers developing RNA therapeutics. The company operates an integrated platform, eCOMPASS, that combines AI-powered RNA sequence design (eNAVIGATE), in-house IVT prototyping, and nucleotide-resolution sequencing-based characterization (eMERGE) in a single iterative workflow. Beneath the integrated platform sits a portfolio of proprietary assays including eSHAPE (RNA secondary structure, leveraging an exclusive license to the NAI chemical), eRibo Pro (sole licensee of Ribo-Seq patents US 8,486,865, 9,284,547, and 9,677,068), eSENSE dsRNA, eSENSE Break, eSENSE m6A, End-Seq, m6A-eCLIP, miR-eCLIP+, RBP-eCLIP, and Oxford Nanopore long-read sequencing. The eVERSE product line monetizes nine years of proprietary RNA datasets (1M+ data points) as AI-ready training data for external drug discovery models.

The company reports 300+ partners including 80% of top biopharma companies by revenue, with named enterprise customers such as Alnylam, CSL Behring, Acuitas Therapeutics, Deep Genomics, Nanovation, and Ribometrix. Revenue mechanics rest on three streams: (1) long-term end-to-end biopharma partnerships using the full eCOMPASS platform, (2) project-based individual capability engagements for biotech and academic researchers (including the Data Catalyst Award and mRNA Innovators Award grant programs), and (3) AI-ready dataset licensing through eVERSE. Pricing is quote-based and not publicly disclosed. Go-to-market is direct enterprise field sales supported by webinars, conference presence (mRNA-Based Therapeutics Summit, DIA Oligonucleotide-Based Therapeutics Conference, mRNA Health Conference), the RNA Insights podcast, and a global manufacturing partner network for GMP scale-up.

The company is led by co-founder Peter Chu (CEO and Chairman), with Chief Technology Officer Iain McFadyen (formerly of Moderna's founding computational science team) and a board including former Novartis CEO Daniel Vasella, UCSD professor and co-founder Gene Yeo, and iGlobe Venture Partner Sidney Yee. Eclipsebio has raised approximately $14 million in a March 2022 Series A co-led by Alexandria Venture Investments and iGlobe, an additional SEC-registered exempt offering of approximately $7.2 million filed in November 2025, and acquired Terrain Bio in January 2026 to add AI/ML RNA design and R&D-scale mRNA manufacturing capabilities.

Name

Eclipse Bioinnovations

Legal name

Eclipse Bioinnovations, Inc.

Website

https://eclipsebio.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Eclipse Bioinnovations is an RNA genomics company offering an integrated AI-enabled platform (eCOMPASS) for RNA therapeutic design, prototyping, and nucleotide-level characterization, serving 300+ pharmaceutical, biotech, and academic partners worldwide.

Ownership category

akta.pro rank

Product category

RNA Therapeutics Development Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Software Publishers (5132)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)

Keywords

• RNA therapeutic development
• AI RNA sequence design
• IVT RNA characterization
• RNA sequencing analytics
• MRNA drug development services

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. End-to-End Biopharma Partnerships: Comprehensive long-term engagements for RNA therapeutic development using the full eCOMPASS platform, encompassing AI design, prototyping, and characterization services.
2. Project-Based Academic Services: Individual capability engagements for academic researchers needing specific assays or datasets from the RNA profiling portfolio.
3. AI-Ready Dataset Licensing: Access to eVERSE platform datasets for AI model training in drug discovery, including RNA structure, UTR, and miRNA binding datasets.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Eclipsebio provides RNA therapeutic development services and an integrated platform (eCOMPASS) combining AI-powered RNA sequence design, R&D-scale IVT RNA prototyping, and nucleotide-resolution sequencing-based characterization. The company sells end-to-end biopharma partnerships, project-based individual assay services (eSHAPE, eRibo Pro, eSENSE variants, eCLIP assays, End-Seq, Nanopore), and AI-ready dataset licensing through eVERSE to pharmaceutical, biotechnology, and academic customers globally.

Product overview

Eclipsebio offers eCOMPASS, an integrated lab-in-the-loop platform for RNA therapeutic development that combines three core capabilities: eNAVIGATE (AI-powered sequence design), rapid prototyping (IVT RNA manufacturing), and eMERGE (sequencing-based characterization). The platform supports programs across vaccines, CAR-T therapies, gene editing, and protein replacement. Beyond the integrated platform, Eclipsebio provides individual analytical capabilities including eSENSE assays (dsRNA detection, RNA fragmentation mapping, m6A methylation), eSHAPE (RNA structure), m6A-eCLIP, miR-eCLIP+, RBP-eCLIP, End-Seq (UTR mapping), and eRibo Pro (ribosome profiling). The eVERSE platform provides AI-ready datasets derived from these assays for model training. The company acquired Terrain Bio in January 2026 to add AI design and manufacturing capabilities, and expanded eCOMPASS with eSENSE Break in June 2026.

Differentiator

Problem solved

Functional benefit

Brands

• eCOMPASS: AI-enabled lab-in-the-loop platform for RNA therapeutic development combining AI-optimized design (eNAVIGATE), rapid prototyping, and sequencing-based characterization (eMERGE)
• eNAVIGATE
• eMERGE
• eVERSE
• eSENSE Break
• eSENSE dsRNA
• eSENSE m6A
• eSHAPE
• eRibo Pro
• End-Seq
• miR-eCLIP+

Products and services

• eCOMPASS Platform Integrated lab-in-the-loop platform combining AI-powered RNA design (eNAVIGATE), rapid prototyping at R&D scale, and deep sequencing-based characterization (eMERGE) into a single iterative workflow for RNA therapeutic development. Supports programs across vaccines, CAR-T therapies, gene editing, and protein replacement for biopharma and biotech customers.
• eVERSE Platform providing reproducible, AI-ready datasets for machine learning model training in drug discovery. Covers multiple assay types including eSHAPE structure data, End-Seq UTR data, and miR-eCLIP+ binding data, formatted for direct integration into AI/ML workflows and model training pipelines.
• End-Seq High-resolution UTR mapping technology identifying active UTRs through nucleotide-level mapping of transcription start sites (5' End-Seq) and polyadenylation sites (3' End-Seq). Supports identification of druggable targets and optimal UTR selection for mRNA therapeutics.
• eRibo Pro Combines RNA-Seq for gene expression with exclusively licensed ribosome profiling method (Ribo-Seq) to provide multidimensional insights into transcription and translation. Sole licensee of the Ribo-Seq method covered by U.S. Patent Numbers 8,486,865, 9,284,547, and 9,677,068.
• eSENSE Break Sequencing-based technology mapping RNA fragmentation and circular RNA nicking sites at single-nucleotide resolution. Uses next-generation sequencing to generate positional maps of fragmentation sites across linear mRNA, self-amplifying RNA, and circular RNA therapeutics.
• eSENSE dsRNA Sequencing-based assay measuring and reducing dsRNA contamination in IVT RNA. Locates where dsRNA formation occurs at single nucleotide resolution, revealing exactly where to make changes to reduce immunogenicity risk.
• eSENSE m6A Enhanced MeRIP-Seq technology mapping N6-methyladenosine (m6A) regions of RNA methylation transcriptome-wide with ultra-low input requirements (down to 2 μg total RNA). Detects large regions of methylation for understanding RNA biology and therapeutic efficacy.
• eSHAPE RNA secondary structure mapping technology using optimized SHAPE-MaP protocol. Provides nucleotide-level measurement of RNA structure in vitro, in LNPs, and in cells. Exclusive licensee of the NAI chemical for SHAPE-MaP structure probing.
• m6A-eCLIP Derived from eCLIP-family assays, detects both large methylated regions and specific bases that are methylated. Provides base-level mapping of methylation for higher resolution analysis compared to eSENSE m6A.
• miR-eCLIP+ Identifies miRNA binding and siRNA off-targets transcriptome-wide. Enables precise mapping of miRNA-mRNA interactions for RNAi and ASO therapeutic development, generating BAM files and aligned sequencing data.
• RBP-eCLIP Identifies where and how RNA-binding proteins bind to transcripts, revealing protein-RNA interaction landscapes for understanding regulatory mechanisms and therapeutic targeting.
• Nanopore Sequencing Long-read RNA sequencing capability using Oxford Nanopore Technologies. Enables direct reading of entire RNA sequences for poly(A) tail length determination, full transcript profiling, and integrity characterization at single-nucleotide resolution.

Quantifiable outcome

• 400% increase in protein expression and 58% increase in editing efficiency for Cas9 mRNA candidates in internal case studies, outperforming both industry-standard codon optimization and state-of-the-art foundation models.
• +1 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature11 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Oxford Nanopore TechnologiescoreTechnology or Integration · 2 April 2026Co-hosted webinar on de-risking RNA therapeutics with high-resolution sequencing. Eclipsebio's eMERGE platform uses Oxford Nanopore sequencing for long-read RNA analysis and characterization.
• Terrain BiocoreStrategic or Co-development Partner · 26 January 2026Acquired in January 2026 to integrate AI/ML RNA design and manufacturing analytics capabilities. Terrain Bio brings machine learning models for RNA sequence optimization and R&D-scale mRNA manufacturing platform. Combined entity creates end-to-end Design, Make, Test platform for RNA therapeutics.
• Alliance for mRNA MedicinesminorStrategic or Co-development Partner · 28 October 2025Eclipsebio participated in AMM-hosted webinar on characterization of mRNA drug product, exploring approaches including next-generation sequencing and cryo-EM.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Tessera Therapeutics: Gene writing and RNA engineering platform company focused on programmable therapeutics. Direct comparable because Eclipsebio's CTO Iain McFadyen was previously Chief Data Science Officer at Tessera, both firms operate in RNA therapeutic design and manufacturing, and both target similar top-biopharma customers with platform-based offerings.
• Alnylam Pharmaceuticals: Leading commercial-stage RNAi therapeutics company. Comparable because Alnylam is both a named Eclipsebio customer and a representative biopharma buyer of siRNA off-target binding analysis services, while also being a direct competitor in the broader RNAi therapeutics space.

Emerging players

• Strand Therapeutics: Synthetic biology company developing programmable mRNA therapeutics with controlled expression profiles. Comparable as an early-stage platform peer operating in mRNA therapeutic design and development, intersecting with Eclipsebio's customer base of mRNA developers across pharma and biotech.
• Nutcracker Therapeutics: Integrated mRNA therapeutics company combining design, manufacturing, and characterization for cancer and infectious disease programs. Directly comparable because Nutcracker similarly emphasizes an integrated design-make-test approach for mRNA, the same modality focus as Eclipsebio's eCOMPASS platform.
• Shape Therapeutics: RNA programming company combining RNA biology and AI/ML to develop gene therapy and RNA editing therapeutics. Comparable as an emerging platform peer in RNA engineering and AI-driven sequence design, targeting similar next-generation RNA therapeutic applications as Eclipsebio's eCOMPASS workflow.

Broad incumbents

• BioNTech: Major mRNA therapeutics and immunotherapy company with extensive internal capabilities across RNA design, manufacturing, and analytics. Comparable as a broad incumbent in the RNA therapeutic space that could both buy Eclipsebio's analytics services and represent an eventual in-house competitor for similar workflows.
• Schrödinger: Computational drug discovery platform company providing physics-based and AI-driven software for molecular design. Comparable as a broader incumbent in AI-driven drug discovery, with overlapping customer base in pharma and biotech, and as a potential competitor for AI-trained on RNA and nucleic acid datasets.
• Recursion Pharmaceuticals: Techbio company combining high-throughput biology, AI, and automation for drug discovery. Comparable as a broader incumbent in the AI-driven biotech platform category, with a similar go-to-market to biopharma and overlapping customer profiles in computational biology and data licensing.
• Charles River Laboratories: Large global CRO and CDMO offering research models, preclinical, and biologics services including emerging RNA therapeutic characterization. Comparable as a broad incumbent CRO that competes for the same biopharma R&D services budget and could bundle competing offerings for RNA therapeutic programs.
• Catalent: Global CDMO providing biologics manufacturing, fill-finish, and analytical services across modalities including mRNA. Comparable as a broad incumbent CDMO with overlapping analytical and CMC capabilities for RNA therapeutic customers and established relationships with top biopharma accounts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eclipse-bioinnovations
• Xx.com/bio_eclipse
• Facebookfacebook.com/eclipsebio

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eclipse Bioinnovations